Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.06 | N/A | +12.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.06 | N/A | +12.47% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their research and development efforts. They acknowledged the competitive landscape but are optimistic about future prospects.
Management highlighted ongoing developments in their pipeline.
They expressed confidence in their long-term strategy despite current challenges.
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted negatively, declining by 0.77%. The lack of revenue data and guidance may have contributed to investor caution, as they seek clearer indicators of future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Nov 6, 2017